CervoMed is trading at $2.67, up 5.12%, amid a neflamapimod dosing update that may be a company-specific catalyst; the release did not explicitly link the move to the news. - On September 28, 2026, CervoMed announced a new 50 mg neflamapimod tablet, FDA removal of a prior drug-exposure limit, and plans to advance a 100 mg twice-daily regimen in future trials. - The update provides dosing flexibility and a formulation designed for twice-daily use. Broader markets were down, and no volume data was provided.